Article Per Year (5 Year)
p-Index From 2021 - 2026
0.562
P-Index
This Author published in this journals
All Journal PAKDEMAS : Jurnal Pengabdian Kepada Masyarakat JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia
Kynaya, Erlangga Masykur
Unknown Affiliation
Religion Agriculture, Biological Sciences & Forestry Arts Humanities Astronomy Automotive Engineering Biochemistry, Genetics & Molecular Biology Chemical Engineering, Chemistry & Bioengineering Chemistry Civil Engineering, Building, Construction & Architecture Computer Science & IT Control & Systems Engineering Decision Sciences, Operations Research & Management Dentistry Earth & Planetary Sciences Economics, Econometrics & Finance Education Electrical & Electronics Engineering Engineering Environmental Science Health Professions Immunology & microbiology Industrial & Manufacturing Engineering Languange, Linguistic, Communication & Media Law, Crime, Criminology & Criminal Justice Library & Information Science Materials Science & Nanotechnology Mathematics Mechanical Engineering Medicine & Pharmacology Neuroscience Nursing Physics Public Health Social Sciences Transportation Veterinary Other

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

 1 
ENHANCING THE COMPETITIVENESS OF LOCAL COFFEE THROUGH INNOVATION IN PROCESSING, BRANDING, AND MARKETING IN GENGGELANG VILLAGE, NORTH LOMBOK Ivo Yekti Nadirah; Kynaya, Erlangga Masykur; Khansa Saifany Zuhri; Marina Kurniasari; Dimas Ahmad Al Hakami; Nabila Alya Azzahra; Lalu Haikal Pasha Ahmad; Zaenab Nur Azkiai; Zidan Fahmi Az Zahir; Muhammad Rafif Fajriatmaja
PAKDEMAS : Jurnal Pengabdian Kepada Masyarakat Vol 4 No 3 (2025): Agustus
Publisher : Fakultas Pertanian

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.58222/pakdemas.v4i3.456

Abstract

Genggelang Village in North Lombok Regency, West Nusa Tenggara, holds significant potential as a coffee-producing region, with over 50% of its land dedicated to coffee farming. However, most farmers continue to sell unprocessed green beans, missing the opportunity to increase value through post-harvest processing, branding, and market access. This community service initiative, carried out under the KKN Universitas Sebelas Maret (UNS) program, aimed to enhance local awareness and capacity in coffee innovation. Socialization activities were conducted directly in the village’s residential centers to ensure accessibility and participation. Findings revealed that farmers face cognitive and systemic barriers, including limited knowledge of fermentation, roasting, and marketing strategies. Many were unaware of the potential income boost from processing and branding. However, the involvement of local practitioners (a café owner and a coffee exporter) and the interactive format encouraged high engagement and motivation. Participants expressed a willingness to collaborate on product development and marketing, signaling a positive shift toward self-sufficiency. This initiative demonstrates that targeted, community-based outreach can uncover and address key developmental gaps, laying the groundwork for a sustainable local coffee industry.
Cardiovascular Adverse Event Risk in Rheumatoid Arthritis Patients Treated with JAK Inhibitor Tofacitinib versus TNF Inhibitors: a Systematic Review, Meta Analysis, and Meta Regression Kynaya, Erlangga Masykur; Salfistra, Nadia Ramadhina; Hanun, Jauza' 'Athifah
JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia Book of Abstrack RCIMS 2025
Publisher : BAPIN-ISMKI (Badan Analisis Pengembangan Ilmiah Nasional - Ikatan Senat Mahasiswa Kedokteran Indonesia)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.53366/jimki.vi.949

Abstract

Rheumatoid arthritis (RA) is a chronic autoimmune disease, often requiring potent therapies like Tofacitinib or TNF inhibitors. Yet the comparative cardiovascular safety profile of these agents remains a critical and evolving concern. Previous meta-analysis revealed major adverse cardiovascular events (MACE) and thromboembolism was prevalent in tofacitinib treated patients. However, the impact of patient comorbidities on cardiovascular adverse events remains uncertain, requiring systematic assessment through meta-analysis and meta-regression. This study aims to assess the risk of cardiovascular adverse events in RA patients treated with tofacitinib versus TNF inhibitors and to evaluate the influence of baseline comorbidities through meta-regression. A comprehensive search of PubMed, Scopus, Scilit, and Epistemonikos identified RCTs and observational studies up to 2025. Random-effects meta-analysis in R estimated pooled OR and HR for MACE and thromboembolism, while patient comorbidities were evaluated through meta-regression. Four studies (n = 62,009) met inclusion criteria. Tofacitinib was associated with increased risk of MACE (HR = 1.33; 95% CI 1.08–1.65; p = 0.008; I² = 0%) and thromboembolism (HR = 1.79; 95% CI 1.23–2.60; p = 0.002; I² = 37.8%) compared with TNF inhibitors. Meta-regression revealed no significant effect of age, sex, hypertension, diabetes, smoking, heart failure, coronary artery disease, venous thromboembolism history, or corticosteroid use on these risks. Tofacitinib increases the risk of MACE and thromboembolism in RA patients compared with TNF inhibitors, independent of common cardiovascular comorbidities and baseline characteristics.
Efficacy and Safety of Tyrosine Kinase 2 Inhibitor Deucravacitinib in Psoriasis : A Systematic Review and Drug-Response Meta Analysis of RCTs Putera, Rizky; Onggowasito, Livilia Abigail; Kynaya, Erlangga Masykur
JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia Book of Abstrack RCIMS 2025
Publisher : BAPIN-ISMKI (Badan Analisis Pengembangan Ilmiah Nasional - Ikatan Senat Mahasiswa Kedokteran Indonesia)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.53366/jimki.vi.961

Abstract

Psoriasis is a chronic immune-mediated disease affecting 1–3% of the population worldwide and often impairs quality of life, with moderate-to-severe cases requiring systemic therapy. Deucravacitinib, a selective tyrosine kinase 2 (TYK2) inhibitor that modulates IL-23, IL-12, and type I interferon pathways, has emerged as a promising oral therapy. However, trial findings remain inconsistent, highlighting the need for systematic evaluation of its efficacy and safety versus placebo.  A comprehensive literature search of PubMed, Scopus, Scilit, and ScienceDirect was performed to identify randomized controlled trials published up to 2025 comparing deucravacitinib with placebo in psoriasis. Risk of bias was assessed using the Cochrane RoB 2.0 tool, and meta-analysis was conducted with Rstudio with random effect model and REML estimator. Seven RCTs (n = 3,014) were included. Deucravacitinib significantly improved PASI-75 (OR = 9.85; 95% CI 5.11–19.01; p < 0.0001), PASI-90 (OR = 14.29; 95% CI 9.14–22.35; p < 0.0001), and PASI-100 (OR = 12.03; 95% CI 5.55–26.09; p < 0.0001), as well as sPGA 0/1 (OR = 14.28; 95% CI 9.30–23.62; p < 0.0001). Quality-of-life outcomes also improved: PSSD-0 (OR = 7.60; 95% CI 2.73–21.16; p = 0.0001) and DLQI 0/1 (OR = 6.27; 95% CI 4.68–8.41; p < 0.0001). Upper respiratory tract infection and acne were more frequent with deucravacitinib, while other adverse events were comparable to placebo. Meta-regression showed dose dependence for DLQI 0/1 (p = 0.02) and PSSD-0 (p = 0.01), but not for adverse events. Deucravacitinib demonstrates significant efficacy and acceptable safety in psoriasis treatment. Long-term studies are warranted to confirm its sustained safety profile.   Keywords: Deucravacitinib, Psoriasis, TYK2 Inhibitor, Efficacy
Co-Authors Dimas Ahmad Al Hakami Hanun, Jauza' 'Athifah Ivo Yekti Nadirah Khansa Saifany Zuhri Lalu Haikal Pasha Ahmad Marina Kurniasari Muhammad Rafif Fajriatmaja Nabila Alya Azzahra Onggowasito, Livilia Abigail Putera, Rizky Salfistra, Nadia Ramadhina Zaenab Nur Azkiai Zidan Fahmi Az Zahir